Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting...

Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting -- Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P1 receptor without associated lymphopenia IND filing on track for...

Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a...

Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology’s Annual Meeting EVANSTON, Ill., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...

Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting WALTHAM, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...